|Bid||2.7000 x 800|
|Ask||2.7100 x 1800|
|Day's Range||2.6300 - 2.7300|
|52 Week Range||1.7400 - 5.1000|
|Beta (3Y Monthly)||0.67|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.80|
If you own shares in Chimerix, Inc. (NASDAQ:CMRX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volatili...
Following the sudden departure of its last CEO earlier this year, Chimerix has tapped a pair of Endocyte executives to lead the company.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 8) Alector Inc (NASDAQ: ALEC ) Denali Therapeutics Inc ...
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announces the appointment of Michael A. Sherman, former Chief Executive Officer of Endocyte, Inc., as Chief Executive Officer of Chimerix, effective immediately.
One of Chimerix's development and commercial partners is out, disclosing this week it would be terminating a four-year-old licensing agreement after deciding to drop Chimerix's drug – the second time in less than five years the drug has been abandoned.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...
– Reports Positive Preliminary Top-line Data from Second Rabbitpox Study – – Type C Meeting Requested with FDA Regarding Virologic Endpoint – – Conference Call at 8:30.
DURHAM, N.C., March 04, 2019 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced.
DURHAM, N.C., Feb. 26, 2019 -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today.
Decreased HHV-6 Reactivation Observed Among Oral Brincidofovir Allogeneic Hematopoietic Cell Transplantation Recipients Results to be Presented at Transplantation and Cellular.
Following former Chimerix CEO Michelle Berrey’s sudden resignation, the company has detailed her severance package this week in an SEC filing.
NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
To fill the hole left by the sudden resignation of Michelle Berrey as the president and CEO of Chimerix, its board has appointed three company executives to serve in the interim capacity.
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M. Michelle Berrey, M.D., M.P.H., has resigned from her role as Chimerix President and Chief Executive Officer. W. Garrett Nichols, Timothy W. Trost and Michael A. Alrutz have been appointed as members of a newly created position, the Office of the Chief Executive Officer, on an interim basis until a replacement is found.
Every investor in Chimerix, Inc. (NASDAQ:CMRX) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease Read More...
Illumina's (ILMN) management is optimistic about witnessing solid demand across the NovaSeq portfolio, which also includes the S2 and S1 flow cells.
Abbott (ABT) is showing a steady rise on a healthy growth graph within its Diabetes Care business for a considerable period.
Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 10:00 a.m. PT (1:00 p.m. ET) at the Westin Saint Francis Hotel in San Francisco, CA. Dr. Berrey will present a corporate overview with plans and expected milestones for 2019, which will highlight the Company's core focus on progressing both oral, short-course brincidofovir (BCV) and the intravenous (IV) BCV program. Following planned discussions with FDA, the Company intends to progress IV BCV into a proof-of-concept study for the treatment of BK virus in kidney transplant recipients, while completing the phase 2 studies initiated during 2018 of IV BCV in adult stem cell transplant recipients with adenovirus infection.
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in October, blaming macroeconomic conditions and unpredictable events that hit several sectors, with healthcare among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent declines. […]
As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.
M. Berrey became the CEO of Chimerix, Inc. (NASDAQ:CMRX) in 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we Read More...